Comparative effectiveness of diosmin and hesperidin combination in patients with chronic venous insufficiency
- 作者: Kseneva S.1, Trifonova O.1, Zolotarev A.1, Pikhtunova E.1, Udut V.1
-
隶属关系:
- Tomsk National Research Medical Centre of the Russian Academy of Sciences
- 期: 卷 36, 编号 6 (2025)
- 页面: 27-30
- 栏目: Pharmacology
- URL: https://journals.eco-vector.com/0236-3054/article/view/686575
- DOI: https://doi.org/10.29296/25877305-2025-06-05
- ID: 686575
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
详细
Objective. Comparative analysis of the therapeutic efficacy of the combined preparation of diosmin and hesperidin in two cohorts of patients with chronic venous insufficiency (CVI) stratified by body mass index.
Material and methods. A prospective clinically controlled study of the efficacy of therapy with the combination of diosmin and hesperidin in 104 patients with chronic venous diseases (C0-C3 according to CEAR) was carried out. The efficacy of pharmacotherapy was assessed by comparative analysis between the group of patients with excessive body weight and the group with normal anthropometric indices.
Results. After 8 weeks of treatment with the combination of diosmin and hesperidin a significant decrease in the severity of discomfort in the lower extremities, intensity of heaviness, leg pain and the feeling of leg oedema was observed (p<0,01). The effect of the therapy in both groups was a decrease in the volume of the lower leg and improvement of the CIVIQ-20 quality of life scores (p<0.01).
Conclusion. The obtained data indicate comparable high efficacy of the combination of diosmin and hesperidin for treatment of clinical manifestations of CVI in patients with both normal and overweight.
全文:
作者简介
S. Kseneva
Tomsk National Research Medical Centre of the Russian Academy of Sciences
编辑信件的主要联系方式.
Email: zolotarevf_aleksey@inbox.ru
ORCID iD: 0000-0002-5448-3752
SPIN 代码: 8644-9420
E.D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, MD
俄罗斯联邦, TomskO. Trifonova
Tomsk National Research Medical Centre of the Russian Academy of Sciences
Email: zolotarevf_aleksey@inbox.ru
ORCID iD: 0000-0001-9425-5765
SPIN 代码: 6839-7035
E.D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, MD
俄罗斯联邦, TomskA. Zolotarev
Tomsk National Research Medical Centre of the Russian Academy of Sciences
Email: zolotarevf_aleksey@inbox.ru
ORCID iD: 0009-0004-8878-9524
SPIN 代码: 2993-9722
E.D. Goldberg Research Institute of Pharmacology and Regenerative Medicine
俄罗斯联邦, TomskE. Pikhtunova
Tomsk National Research Medical Centre of the Russian Academy of Sciences
Email: zolotarevf_aleksey@inbox.ru
ORCID iD: 0009-0003-8741-0722
SPIN 代码: 5958-3183
E.D. Goldberg Research Institute of Pharmacology and Regenerative Medicine
俄罗斯联邦, TomskV. Udut
Tomsk National Research Medical Centre of the Russian Academy of Sciences
Email: zolotarevf_aleksey@inbox.ru
ORCID iD: 0000-0002-3829-7132
SPIN 代码: 8645-9815
E.D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Corresponding member of the Russian Academy of Sciences, MD
俄罗斯联邦, Tomsk参考
- Phelps H.N., Singleton R.K., Zhou B. et al. Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024; 403 (10431): 1027–50. doi: 10.1016/S0140-6736(23)02750-2
- Davies H.O., Popplewell M., Singhal R. et al. Obesity and lower limb venous disease - The epidemic of phlebesity. Phlebology. 2017; 32 (4): 227–33. doi: 10.1177/0268355516649333
- Langan E.A., Wienandt M., Bayer A. et al. Effect of obesity on venous blood flow in the lower limbs. J Dtsch Dermatol Ges. 2023; 21 (6): 622–9. doi: 10.1111/ddg.15062
- Kirienko A., Radak D., Maggioli A. Clinical efficacy of once-daily micronized purified flavonoid fraction 1000 mg tablet in patients with symptomatic chronic venous disease. Curr Med Res Opin. 2018; 35: 1–15. doi: 10.1080/03007995.2018.1499508
- Smith P.D. Micronized purified flavonoid fraction and the treatment of chronic venous insufficiency: microcirculatory mechanisms. Microcirculation. 2000; 7 (6 Pt 2): 35–40.
- Lurie F., Branisteanu D.E. Improving Chronic Venous Disease Management with Micronised Purified Flavonoid Fraction: New Evidence from Clinical Trials to Real Life. Clin Drug Investig. 2023; 43 (Suppl 1): 9–13. doi: 10.1007/s40261-023-01261-y
- Богачев В.Ю., Болдин Б.В., Варич Г.А. и др. Хронические заболевания вен и ожирение: патогенетически обоснованные возможности лечения и профилактики. Амбулаторная хирургия. 2024; 21 (1): 64–73 [Boldin B.V., Boldin B.V., Varich G.A. et al. Chronic venous diseases and obesity: pathogenetically based treatment and prevention options. Ambulatory Surgery (Russia). 2024; 21 (1): 64–73 (in Russ.)]. doi: 10.21518/akh2024-014
- Petrascu F.M., Matei S.C., Margan M.M. et al. The Impact of Inflammatory Markers and Obesity in Chronic Venous Disease. Biomedicines. 2024; 12 (11): 2524. doi: 10.3390/biomedicines12112524
- Головина В.И., Золотухин И.А. Применение диосминсодержащих препаратов в лечении хронических заболеваний вен. Лечебное дело. 2023; 2: 67–73 [Golovina V. I., Zolotukhin I. A. The Use of Diosmin Drugs in the Treatment of Chronic Venous Insufficiency. Lechebnoe delo. 2023; 2: 67–73 (in Russ.)]. doi: 10.24412/2071-5315-2023-12881
- Талибов О.Б. Фармакология препаратов, применяющихся при хронических заболеваниях вен. Хирургия. Журнал им. Н.И. Пирогова. 2019; 2: 106–9 [Talibov O.B. Pharmacology of the drugs prescribed for chronic venous diseases. Pirogov Russian Journal of Surgery. 2019; 2: 106–9 (in Russ.)]. doi: 10.17116/hirurgia2019021106
补充文件
